A Phase 1B/2, Multicenter, Open-Label, Safety, Tolerability, and Activity Study of SYNT001 in Patients With Warm Autoimmune Hemolytic Anemia (WAIHA)
Latest Information Update: 03 Nov 2023
At a glance
- Drugs Orilanolimab (Primary)
- Indications Autoimmune haemolytic anaemia
- Focus Adverse reactions
- Acronyms WAIHA
- Sponsors Alexion AstraZeneca Rare Disease; Syntimmune
- 19 Sep 2019 Status changed from recruiting to discontinued.
- 17 May 2018 According to a Syntimmune media release, interim data from this trial is expected in the second half of 2018.
- 01 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Jan 2019.